In 2023, Pfizer acquired the Sanford North facility. Once operational, the 20-acre facility has the capabilities for producing biologics and provides additional manufacturing capacity allowing Pfizer to help accelerate its innovative pipeline.
The North Creek site, integrated into Pfizer’s network following the Seagen acquisition, produces antibody drug conjugates (ADCs) and antibody intermediates.
The 230-acre site in Sanford, North Carolina site has flexible, multi-product manufacturing capabilities and facilities.
The Rocky Mount, North Carolina site has 1.4 million square feet of manufacturing space on 250 acres in Eastern North Carolina.
In Rochester, Michigan, the site manufactures and packages penicillin, the only approved treatment for late stage syphilis.
With more than 100 years of rich history in innovation and manufacturing excellence, 19 products- including various vaccines, antibiotics, and oncology medicines, have been discovered, developed, and approved at the Pearl River, New York site.
Since 1982, the Middleton site has focused on the manufacture of biologics. The 83,000-square-foot facility isolates bovine thrombin, a naturally occurring enzyme which plays a critical role in rapid clotting (hemostasis) of blood.
The McPherson site specializes in manufacturing sterile injectable medicines used daily in hospitals around the world.
The 1,300 acre facility located in Kalamazoo, Michigan manufactures active pharmaceutical ingredients (API) and drug product (DP).
In Franklin, our 48,000-square-foot facility manufactures heparin active pharmaceutical ingredient (API).
The 70-acre site in Andover combines state-of-the-art research and development facilities with flexible, multi-product manufacturing capabilities.